| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 23.05.
| UCB – Da sieht weiterhin bullisch aus | | 9 | GodmodeTrader.de |
| 18.05.
| UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 | | 44 | PR Newswire |
| ATLANTA, May 18, 2012 /PRNewswire/ -- UCB, Inc., a leading biopharmaceutical company dedicated to the research and development of treatments for severe central nervous system and immunological disorders...
Mehr lesen zu:
UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012 | |
| 18.05.
| S&P Equity senkt UCB auf 'Sell' - Ziel 33 Euro | | 168 | APA-dpa-AFX-Analyser |
| Das Analysehaus S&P Equity hat UCB von
"Hold" auf "Sell" abgestuft und das Kursziel auf 33,00 Euro
belassen. Der hohe Bewertungsaufschlag im Vergleich zu den Aktien
der Wettbewerber sei nicht...
Mehr lesen zu:
S&P Equity senkt UCB auf 'Sell' - Ziel 33 Euro | |
| 16.05.
| Even as UCB's Keppra Captures the Largest Patient Share, Followed by GSK's Lamictal, Strong Company Support and Positive Efficacy Performance Drive Uptake of UCB's Vimpat in the Epilepsy Market, According to a Recent BioTrends Report | | 32 | Business Wire |
| BioTrends Research Group, one of the world's leading research and
advisory firms for specialized biopharmaceutical issues, finds that
almost
all pharmacotherapy-treated...
Mehr lesen zu:
Even as UCB's Keppra Captures the Largest Patient Share, Followed by GSK's Lamictal, Strong Company Support and Positive Efficacy Performance Drive Uptake of UCB's Vimpat in the Epilepsy Market, According to a Recent BioTrends Report | |
| 09.05.
| UCB - Käufer geben mächtig Gas | | 19 | GodmodeTrader.de |
| 30.04.
| XFRA DIVIDEND INFORMATION - 30.04.2012 - 5 | | 238 | Xetra Newsboard |
| FOLGENDE WERTPAPIERE WERDEN AM 30.04.2012 EX DIVIDENDE GEHANDELT.
THE EX-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 30.04.2012.
INSTR EXCH ISIN INSTRUMENT NAME DIVIDEND AMOUNT
UZA XFRA CH0010567961...
Mehr lesen zu:
XFRA DIVIDEND INFORMATION - 30.04.2012 - 5 | |
| 30.04.
| XETI DIVIDEND INFORMATION - 30.04.2012 - 2 | | 277 | Xetra Newsboard |
| FOLGENDE WERTPAPIERE WERDEN AM 30.04.2012 EX DIVIDENDE GEHANDELT.
THE EX-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 30.04.2012.
INSTR EXCH ISIN INSTRUMENT NAME DIVIDEND AMOUNT
BYG XETI FR0000120503...
Mehr lesen zu:
XETI DIVIDEND INFORMATION - 30.04.2012 - 2 | |
| 27.04.
| XFRA UNC: AUSSETZUNG/SUSPENSION | | 36 | Xetra Newsboard |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT:
THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
UCB S.A. UNC BE0003739530 HZE/EOT
Mehr lesen zu:
XFRA UNC: AUSSETZUNG/SUSPENSION | |
| 27.04.
| XETI H UNC: AUSSETZUNG/SUSPENSION | | 32 | Xetra Newsboard |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT:
THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
UCB S.A. UNC BE0003739530 HZE/EOT
Mehr lesen zu:
XETI H UNC: AUSSETZUNG/SUSPENSION | |
| 24.04.
| Infraserv Höchst geht fremd: Betrieb des UCB-Campus in Monheim | | 10 | Chemie Technik |
| 18.04.
| UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology | | 51 | PR Newswire |
| ATLANTA, April 18, 2012 /PRNewswire/ --UCB, a leading biopharmaceutical company committed to the development of new epilepsy treatments and research, will sponsor multiple sets of...
Mehr lesen zu:
UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology | |
| 05.04.
| Research and Markets: Belgium Pharmaceuticals and Healthcare Report Q2 2012 - In 2012, Belgian Pharmaceutical Company UCB and Japanese Firm Otsuka Pharmaceutical Amended Their Collaboration to Focus on CNS Disorders | | 91 | Business Wire |
| Research and Markets (http://www.researchandmarkets.com/research/42209237/belgium_pharmaceut)
has announced the addition of the "Belgium
Pharmaceuticals and Healthcare...
Mehr lesen zu:
Research and Markets: Belgium Pharmaceuticals and Healthcare Report Q2 2012 - In 2012, Belgian Pharmaceutical Company UCB and Japanese Firm Otsuka Pharmaceutical Amended Their Collaboration to Focus on CNS Disorders | |
| 04.04.
| From Earlier: UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis | | 2 | Benzinga.com |
| 04.04.
| UCB,Amgen Begin Sclerostin Antibody Phase 3 Trial In Postmenopausal Osteoporosis | | 100 | AFX News |
| THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced that, along with UCB SA
(UCB), it initiated sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial
program for the treatment of postmenopausal...
Mehr lesen zu:
UCB,Amgen Begin Sclerostin Antibody Phase 3 Trial In Postmenopausal Osteoporosis | |
| 04.04.
| UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis | | 96 | PR Newswire |
| BRUSSELS and THOUSAND OAKS, Calif., April 4, 2012 /PRNewswire/ --UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase...
Mehr lesen zu:
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis | |
| 02.04.
| UCB Shines a Spotlight on the Trials and Triumphs of Living with Epilepsy with the "My Four Words" Project | | 44 | PR Newswire |
| ATLANTA, April 2, 2012 /PRNewswire/ --On March 31, an estimated 5,000 people impacted by epilepsy rallied together on the National Mall in Washington, D.C. at the Epilepsy Foundation's National Walk...
Mehr lesen zu:
UCB Shines a Spotlight on the Trials and Triumphs of Living with Epilepsy with the "My Four Words" Project | |
| 28.03.
| How Would You Describe Epilepsy if You Only Had Four Words? UCB and Epilepsy Advocate' Challenge National Walk for Epilepsy Attendees to Share Their Experience with Epilepsy in Four Words | | 34 | PR Newswire |
| WASHINGTON, March 28, 2012 /PRNewswire/ --For the more than three million Americans who live with epilepsy, gaining seizure control is a top priority. Representatives from UCB and the Epilepsy Advocate...
Mehr lesen zu:
How Would You Describe Epilepsy if You Only Had Four Words? UCB and Epilepsy Advocate' Challenge National Walk for Epilepsy Attendees to Share Their Experience with Epilepsy in Four Words | |
| 23.03.
| UCB: UCB SA/NV: Convocation Annual Shareholders' Mee... | | 6 | InvestEgate |
| 22.03.
| UCB – Ausbruch läuft an | | 24 | GodmodeTrader.de |
| 20.03.
| Taleo to Become UCB's Partner for Global Recruiting Project | | 22 | MarketWire |
| DUBLIN, CA -- (Marketwire) -- 03/20/12 -- Taleo Corporation (NASDAQ: TLEO), a global leader of SaaS-based Talent Management solutions, today announced that global biopharmaceutical leader UCB has...
Mehr lesen zu:
Taleo to Become UCB's Partner for Global Recruiting Project | |
